High-throughput hit finding and compound-profiling technologies for academic drug discovery

Drug Discovery Today: Technologies

Volumn 5, Issue 1, 2008, Pages

  Gribbon, Philip ^a  

^a European Screeningport GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; PHOSPHOTRANSFERASE INHIBITOR;

COMBINATORIAL LIBRARY; COMPUTER PROGRAM; CURRICULUM; DRUG INDUSTRY; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; INVESTMENT; MASS SPECTROMETRY; MEDICAL LITERATURE; PUBLICATION; REVIEW;

EID: 68049117352     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2009.01.003     Document Type: Review

References (40)

1. Verkman A.S. Academia given a helping hand in drug development. Am. J. Physiol. Cell Physiol. 286 (2004) 465-474
2. Kozikowski A.P., et al. Why academic drug discovery makes sense. Science 313 (2006) 1235-1236
3. Tralau-Stewart C.J., et al. Drug discovery: new models for industry -academic partnerships. Drug Discovery Today 14 (2009) 95-101
4. Spring D.R. Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev. 34 (2005) 472-482
5. Michael S., et al. A robotic platform for quantitative high-throughput screening. Assay Drug Dev. Technol. 6 (2008) 637-658
6. Hübel K., et al. Chemical biology - identification of small molecule modulators of cellular activity by natural product inspired synthesis. Chem. Soc. Rev. 37 (2008) 1361-1374
7. Inglese J., et al. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3 (2007) 466-479
8. Bogyo M., et al. Genomics and proteomics: from genes to function: advances in applications of chemical and systems biology. Curr. Opin. Chem. Biol. 11 (2007) 1-3
9. Oprea T.I., et al. Lead-like, drug-like or "Pub-like": how different are they?. J. Comput. Aid. Mol. Des. 21 (2007) 113-119
10. Lazo J.S., et al. Building a pharmacological lexicon: small molecule discovery in Academia. Mol. Pharmacol. 72 (2007) 1-7
11. Clackson T. Translational research in academia and industry. Exp. Biol. Med. 231 (2006) 1685-1689
12. Guilligay D., et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 15 (2008) 500-506
13. Nören-Müller A., et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. U. S. A. 10 (2006) 10606-10611
14. Edwards M., et al. Gold in the ivory tower: equity rewards of outlicensing. Nat. Biotechnol. 24 (2006) 509-515
15. Mitchison T.J. Small-molecule screening and profiling by using automated microscopy. Chembiochem 6 (2005) 33-39
16. Schröter T., et al. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled Luciferase high-throughput screening assays to discover inhibitors of Rho-Kinase II (ROCK-II). J. Biomol. Screen. 13 (2008) 17-28
17. Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 11 (2006) 277-279
18. Gribbon P., et al. High-throughput drug discovery: what can we expect from HTS?. Drug Discov. Today 10 (2005) 17-22
19. Houston J.G., et al. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006. Drug Discovery Today 13 (2008) 44-51
20. Shelat A.A., et al. The interdependence between screening methods and screening libraries. Curr. Opin. Chem. Biol. 11 (2007) 244-251
21. Dolle R.E., et al. Comprehensive survey of chemical libraries for drug discovery and chemical biology. J. Comb. Chem. 10 (2007) 753-802
22. Blow N. Lab automation: tales along the road to automation. Nat. Methods 5 (2008) 109-112
23. Lang P., et al. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 5 (2006) 343-356
24. Snowden M., et al. The impact of diversity-based, high-throughput screening on drug discovery: "Chance favours the prepared mind". Curr. Opin. Drug Discov. Dev. 11 (2008) 553-558
25. Cechetto J.D., et al. High-throughput screening at McMaster University: automation in academe. J. Assoc. Lab. Autom. 9 (2004) 307-311
26. Eggert U.S., et al. Small molecule screening by imaging. Curr. Opin. Chem. Biol. 10 (2006) 232-237
27. Krausz E. High-content siRNA screening. Mol. BioSyst. 3 (2007) 232-240
28. Starkuviene V., et al. The potential of high-content high-throughput microscopy in drug discovery. Br. J. Pharmacol. 152 (2007) 62-71
29. Xiaobo Z., et al. Test informatics challenges of high-throughput microscopy. Signal Process. Mag. 23 (2006) 63-72
30. Sewing A., et al. Helping science to succeed: improving processes in R&D. Drug Discov. Today 13 (2008) 227-233
31. Hofbauer K.G. Academic institutions and industry: bridging the gap. Expert Opin. Drug Discov. 3 (2008) 369-373
32. Baxendale I.R., et al. Pharmaceutical strategy and innovation: an academic's perspective. ChemMedChem 2 (1997) 768-788
33. Scheuermann J., et al. DNA-encoded chemical libraries. J. Biotechnol. 126 (2006) 568-581
34. Morgan, B. et al. [Praecis Pharmaceuticals Incorporated] (2007) Methods for identifying compounds of interest using encoded libraries. USP Application 20070224607
35. Melkko S., et al. Lead discovery by DNA-encoded chemical libraries. Drug Discov. Today 12 (2007) 465-471
36. Lipp E. Compound discovery tools still evolving. Genet. Eng. Biotech. News 28 (2008) 5
37. Daub H. Characterisation of kinase-selective inhibitors by chemical proteomics. Biochim. Biophys. Acta 1754 (2005) 183-190
38. Brehmer D., et al. Cellular targets of gefitinib. Cancer Res. 65 (2005) 379-382
39. Kruse U., et al. Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol. Cell. Proteom. 7 (2008) 1887-1901
40. Brenner S., et al. Encoded combinatorial chemistry. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5381-5383